Related Experiment Video
Updated: Jul 1, 2025
Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports
Published on: November 28, 2019
Cytokines and soluble mediators as architects of tumor microenvironment reprogramming in cancer therapy
Suling Xu1, Qingqing Wang2, Wenxue Ma3
1Department of Dermatology, The First Affiliated Hospital of Ningbo University School of Medicine, Ningbo, Zhejiang 315020, China.
Abstract:
Navigating the intricate landscape of the tumor microenvironment (TME) unveils a pivotal arena for cancer therapeutics, where cytokines and soluble mediators emerge as double-edged swords in the fight against cancer. This review ventures beyond traditional perspectives, illuminating the nuanced interplay of these elements as both allies and adversaries in cancer dynamics. It critically evaluates the evolving paradigms of TME reprogramming, spotlighting innovative strategies that target the sophisticated network of cytokines and mediators. Special focus is placed on unveiling the therapeutic potential of novel cytokines and mediators, particularly their synergistic interactions with extracellular vesicles, which represent underexplored conduits for therapeutic targeting. Addressing a significant gap in current research, we explore the untapped potential of these biochemical players in orchestrating immune responses, tumor proliferation, and metastasis. The review advocates for a paradigm shift towards exploiting these dynamic interactions within the TME, aiming to transcend conventional treatments and pave the way for a new era of precision oncology. Through a critical synthesis of recent advancements, we highlight the imperative for innovative approaches that harness the full spectrum of cytokine and mediator activities, setting the stage for breakthrough therapies that offer heightened specificity, reduced toxicity, and improved patient outcomes.
Insights
Cytokines and soluble mediators in the tumor microenvironment (TME) are key targets for cancer therapy. Novel strategies harness these molecules, often with extracellular vesicles, for precision oncology.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- The tumor microenvironment (TME) is a complex ecosystem crucial for cancer progression and therapeutic response.
- Cytokines and soluble mediators within the TME exhibit dual roles, acting as both promoters and inhibitors of cancer.
- Current therapeutic strategies often overlook the intricate signaling networks within the TME.
Purpose of the Study:
- To critically review the multifaceted roles of cytokines and soluble mediators in cancer.
- To explore innovative TME reprogramming strategies targeting these signaling molecules.
- To highlight the therapeutic potential of novel cytokines, mediators, and their synergy with extracellular vesicles.
Main Methods:
- Comprehensive literature review of recent advancements in TME research.
- Analysis of cytokine and mediator functions in cancer immunity, proliferation, and metastasis.
- Evaluation of extracellular vesicles as therapeutic delivery vehicles.
Main Results:
- Cytokines and mediators significantly influence immune responses, tumor growth, and metastasis.
- Extracellular vesicles offer promising, yet underexplored, avenues for targeted delivery of therapeutic agents.
- Synergistic interactions between novel mediators and extracellular vesicles present new therapeutic opportunities.
Conclusions:
- A paradigm shift towards exploiting TME dynamics is essential for advancing cancer treatment.
- Harnessing the full spectrum of cytokine and mediator activities can lead to more specific and less toxic therapies.
- Precision oncology can be significantly enhanced by targeting these intricate molecular interactions within the TME.
Related Concept Videos
02:17The Tumor Microenvironment
01:27Tumor Immunotherapy
02:40Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:38Mitogens and the Cell Cycle
01:15Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...